355 related articles for article (PubMed ID: 12918763)
21. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease.
Sugita S; Kawazoe Y; Imai A; Yamada Y; Horie S; Mochizuki M
Arthritis Res Ther; 2012 May; 14(3):R99. PubMed ID: 22546542
[TBL] [Abstract][Full Text] [Related]
22. Induction of regulatory T cells by infliximab in Behcet's disease.
Sugita S; Yamada Y; Kaneko S; Horie S; Mochizuki M
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):476-84. PubMed ID: 20861484
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
[TBL] [Abstract][Full Text] [Related]
24. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
Benitez-del-Castillo JM; Martinez-de-la-Casa JM; Pato-Cour E; Méndez-Fernández R; López-Abad C; Matilla M; Garcia-Sanchez J
Eye (Lond); 2005 Aug; 19(8):841-5. PubMed ID: 15389273
[TBL] [Abstract][Full Text] [Related]
25. Case of neuro-Behçet's disease successfully maintained a remission using infliximab for 2 years.
Kanemaru H; Makino T; Jinnin M; Yonemitsu A; Makino K; Ihn H
J Dermatol; 2013 Aug; 40(8):632-4. PubMed ID: 23724912
[TBL] [Abstract][Full Text] [Related]
26. [Behcet's refractory uveitis treated successfully by infliximab].
Mahfoudhi M; Hariz A; Ben Abdelghani K; Turki S; Kheder A
Tunis Med; 2014 Jan; 92(1):41-2. PubMed ID: 24879172
[No Abstract] [Full Text] [Related]
27. Author reply: To PMID 24359625.
Read RW; Levy-Clarke G; Jabs DA; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Oct; 121(10):e58-9. PubMed ID: 25015217
[No Abstract] [Full Text] [Related]
28. Behçet disease-associated uveitis successfully treated with golimumab.
Mesquida M; Victoria Hernández M; Llorenç V; Pelegrín L; Espinosa G; Dick AD; Adán A
Ocul Immunol Inflamm; 2013 Apr; 21(2):160-2. PubMed ID: 23252659
[TBL] [Abstract][Full Text] [Related]
29. Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment.
Yamada Y; Sugita S; Tanaka H; Kamoi K; Takase H; Mochizuki M
Br J Ophthalmol; 2011 Feb; 95(2):205-8. PubMed ID: 20542984
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of infliximab on the acute attack of uveitis.
Alokaily F; Alsaleh S; Al-Balawi M; Al-Rashidi S
Saudi Med J; 2010 Jan; 31(1):82-5. PubMed ID: 20062906
[TBL] [Abstract][Full Text] [Related]
31. Behçet's syndrome: from aetiology to treatment.
Powell RJ
Adv Exp Med Biol; 2003; 528():481-6. PubMed ID: 12918749
[No Abstract] [Full Text] [Related]
32. Re: Levy-Clarke et al.: Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders (Ophthalmology 2014;121:785-96).
Onal S; Tugal-Tutkun I
Ophthalmology; 2014 Oct; 121(10):e57-8. PubMed ID: 25064722
[No Abstract] [Full Text] [Related]
33. [Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication].
van Laar JA; Jamnitski A; Baarsma GS; van Daele PL; van Hagen PM
Ned Tijdschr Geneeskd; 2006 Apr; 150(13):705-9. PubMed ID: 16623340
[TBL] [Abstract][Full Text] [Related]
34. Infliximab for Behçet disease with aortic involvement: two novel case reports without concurrent use of immunosuppressive agents or corticosteroids.
Rokutanda R; Okada M; Yamaguchi K; Nozaki T; Deshpande GA; Kishimoto M
Mod Rheumatol; 2013 Mar; 23(2):412-3. PubMed ID: 22821442
[No Abstract] [Full Text] [Related]
35. Sustained remission after infliximab in a child with vasculitis refractory to conventional immunosuppressives including interferon-alpha.
Evereklioglu C; Borlu M
Br J Ophthalmol; 2008 Aug; 92(8):1034, 1148-9. PubMed ID: 18653594
[No Abstract] [Full Text] [Related]
36. Anti-TNF-alpha therapy for uveitis: Behçet and beyond.
Murray PI; Sivaraj RR
Eye (Lond); 2005 Aug; 19(8):831-3. PubMed ID: 16086039
[No Abstract] [Full Text] [Related]
37. Uveitis in juvenile Behçet's disease: clinical course and visual outcome compared with adult patients.
Kramer M; Amer R; Mukamel M; Snir M; Jaouni T; Friling R
Eye (Lond); 2009 Nov; 23(11):2034-41. PubMed ID: 19151650
[TBL] [Abstract][Full Text] [Related]
38. Refractory neuro-Behçet treated by tocilizumab: a case report.
Urbaniak P; Hasler P; Kretzschmar S
Clin Exp Rheumatol; 2012; 30(3 Suppl 72):S73-5. PubMed ID: 23020826
[TBL] [Abstract][Full Text] [Related]
39. Infliximab in refractory uveitis due to Behçet's disease.
Wechsler B; Sablé-Fourtassou R; Bodaghi B; Huong DL; Cassoux N; Badelon I; Fain O; LeHoang P; Piette JC
Clin Exp Rheumatol; 2004; 22(4 Suppl 34):S14-6. PubMed ID: 15515776
[TBL] [Abstract][Full Text] [Related]
40. [Anti-TNF-α in the treatment of uveitis in the Besançon Hospital].
Fery-Blanco C; Schwartz C; Gil H; Curlier E; Prati C; Delbosc B
J Fr Ophtalmol; 2011 Dec; 34(10):697-702. PubMed ID: 21889230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
